Biomarkers in Dry Eye Disease

The 2017 global definition of dry eye disease - a common, yet poorly managed condition that is prevalent in up to 50% of Asian populations - highlights the importance of loss of tear film homeostasis and neurosensory abnormalities. This research program has developed and validated a suite of techniques and instruments which focus on these two key disease processes.

Competitive advantage

  • Extensive long standing clinical and laboratory based experience in dry eye disease
  • Comprehensive suite of technologies not available elsewhere in Australia
  • Diverse and well-established database of potential study participants. Specialty clinics facilitate targeted patient recruitment (Dry Eye, Red Eye, Contact Lenses, Myopia Control)

Impact

Dry eye affects over 4 million Australian women. It is associated with reduced productivity at work, reduced subjective quality of life, equivalent to severe angina, and a significant and ongoing Medicare burden. Improved diagnostics, particularly those that target the key pathophysiological mechanisms, will enable more appropriate treatment and monitoring of the impact of treatment. 

Successful outcomes

Established track record of clinical studies - Phase 1, first in man - Phase 4 trials.

Capabilities and facilities

  • Measuring sensitivity
  • Subjective symptomatology
  • in vivo confocal microscopy
  • Tear neuropeptides and tear homeostasis

Our Partners

  • Alcon
  • Allergan
  • Bausch + Lomb
  • Coopervision
  • Johnson and Johnson
  • Novartis
  • Stiltec
  • Menicon
  • Azura Ophthalmics